Neoplasms, Colorectal Completed Phase 2 Trials for Irinotecan (DB00762)

Also known as: Colorectal Neoplasms / Colorectal Neoplasm / Neoplasms,Colorectal

IndicationStatusPhase
DBCOND0036298 (Neoplasms, Colorectal)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00967616Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line TherapyTreatment
NCT00730158A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal CancerTreatment
NCT02246049A Multicenter, Clinical Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With mCRCTreatment
NCT00361842Multicenter Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal CancerTreatment
NCT00615056A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line RegimenTreatment
NCT01677884Intra-arterial Hepatic Bevacizumab and Systemic ChemotherapyTreatment
NCT01765582A Study of Sequential and Concurrent FOLFOXIRI/Avastin (Bevacizumab) Regimens Versus FOLFOX/Avastin in First-Line in Participants With Metastatic Colorectal Cancer (STEAM)Treatment